AI and the False Claims Act
Disparate Impact & Enforcement Rollbacks: What’s the Tea in L&E?
What’s in Your Operating Agreement? Legal Tips for Healthcare Providers
A New Brand of Uncertainty? — PE Pathways Podcast
The Rise of OTAs in Defense Contracting: Opportunities, Risks, and What Contractors Need to Know
Breaking the Cycle: Flooding, Infrastructure, and Climate Law in Practice
No Password Required: Former Lead Attorney at U.S. Cyber Command, Cyber Law Strategist, and Appreciator of ‘Mad Men’ Hats
Understanding BBB Ratings: Building Trust and Mitigating Risks — Regulatory Oversight Podcast
Beyond the Bylaws: The Medical Staff Show - Need to Know: How to Manage Medical Staff Confidentiality and Privilege Protections
False Claims Act Insights - The Mathematics of Nuclear FCA Verdicts
PODCAST: Williams Mullen's Benefits Companion - Cost, Care and Captives: A Mid-Size Employer’s Guide to Benefit Trends
Lawyers Beware: There Could Be Serious Ethics Issues With The New AI Browsers
Avoiding a Bored Board
We get Privacy for work – Episode 6: The Potential Privacy Risks Inherent to Mergers and Acquisitions
LathamTECH in Focus: Tech Deals: The Emerging Focus of FDI Regulators?
Podcast - Tips for Maintaining FTC Compliance When Using AI
Compliance Tip of the Day: Rethinking Corporate AI Governance Through Design Intelligence
The Presumption of Innocence Podcast: Episode 66 - Tariff Uncertainty and Compliance Risks for Businesses
Daily Compliance News: July 22, 2025, The I-9 Hell Edition
Why do companies need AI governance policies and procedures? In part because the legal landscape around AI is so unsettled....more
As government scrutiny of the healthcare industry intensifies, enforcement agencies are casting wider nets to recover funds based on narrowly interpreted violations. This puts not only healthcare providers but also those...more
Imagine receiving an email from an unknown actor claiming to have taken approximately 2 terabytes of data from your organization’s network. The threat actor provides a file tree and sample files to substantiate its claim....more
ComplexDiscovery Editor’s Note: The 1H 2025 eDiscovery Business Confidence Survey marks the 37th edition of this trusted industry snapshot, drawing insights from 77 professionals across the legal, technology, and corporate...more
From our M365 Academy Series, learn about the current state of cloud attachments, their behavior in Teams and OneDrive, and why you may need to update your traditional preservation strategies to manage them. ...more
The 1:10:100 rule—coined in 1992 by George Labovitz and Yu Sang Chang, the rule describes how much bad data costs. Preventing the creation of bad data at its source costs $1. Remediating bad data costs $10. Doing nothing...more
Remediation occurs for a host of reasons. You may identify remediation risk from internal activities (e.g., an audit, a control break) or external activities (e.g., a complaint, a regulatory exam, a lawsuit). Sometimes a...more
When we write about data privacy, it’s easy to default to talking to “privacy professionals.” But take a look at the privacy management industry: The privacy program managers, chief privacy officers, and other purely...more
With new collaboration features, AI tools, and work technology developing at a dizzying pace, we know that the volume of data organizations must manage will only increase faster. What are the risks and costs involved with...more
Artificial intelligence (AI), particularly generative AI, thrives on vast amounts of data, fueling AI capabilities, insights, and predictions. But with this reliance on data comes potential privacy and security risks. And...more
Responsible organizations understand that privacy governance is essential for the systematic and compliant management of personal data and for maintaining customer and stakeholder trust. In a world where people increasingly...more
Early in the new year, the US Food and Drug Administration (FDA) released two anticipated draft guidance documents focused on artificial intelligence (AI): Artificial Intelligence-Enabled Device Software Functions: Lifecycle...more
Artificial Intelligence has rapidly moved from theoretical to transformational, profoundly changing how businesses operate across industries. While the benefits of AI, particularly Generative AI (genAI), are monumental, these...more
In the waning days of the Biden administration, the FDA released a flood of new guidance documents and other agency actions, including several important items related to digital health. On January 7, FDA published two new...more
O ano de 2024 representou um período de grande amadurecimento institucional e regulatório para a Autoridade Nacional de Proteção de Dados (ANPD). Em um cenário marcado por avanços tecnológicos acelerados e discussões...more
The Food and Drug Administration (FDA) has recently issued two draft guidance documents aimed at providing recommendations for the use of AI in medical devices and drug and biological product development.These guidance...more
Looking for something more advanced than your average export controls conference? Go beyond the basics at ACI’s 2nd Annual Advanced Forum on Global Export Controls. This premier event offers cutting-edge insights and...more
FDA recently issued two draft guidance documents discussing: (1) the use of artificial intelligence (AI) to produce information to support a regulatory decision about a drug or biological product’s safety, effectiveness, or...more
The Food and Drug Administration (FDA) has recently released two draft guidance documents (Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations and...more
On January 7, 2024, the U.S. Food and Drug Administration (FDA) published the draft guidance “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations,” which...more
The U.S. Food and Drug Administration (FDA) published the draft guidance “Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices,” which provides advice for sponsors, investigators, and...more
On January 7, 2025, FDA published “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff”...more
The FDA has shared draft guidance on the design and development of AI-enabled medical devices and marketing submissions for those devices. The Importance of Engaging Early Sponsors of AI-enabled devices should engage with the...more
The Digital Operational Resilience Act 2022/2554 (DORA) is a European regulation that will come into force on January 17, 2025. The regulation aims to strengthen the digital operational resilience of the financial sector...more
The California Privacy Protection Agency (CPPA), at its board meeting on November 8, 2024, voted 4–1 to advance proposed regulations to a formal rulemaking. As currently drafted, these regulations would, among other things...more